Drug intelligence / Profile preview

Isotonix OPC-3

Development stage
Unknown
Lead developer
Market America
Administration
Oral
01

Overview

Isotonix OPC-3 is a dietary supplement and nutraceutical formulated as an isotonic-capable powder containing a synergistic blend of plant-derived antioxidants, specifically oligomeric proanthocyanidins (OPCs). Developed by Market America, the product features a combination of grape seed extract, red wine extract, bilberry extract, citrus bioflavonoids, and Pycnogenol (a patented extract from French maritime pine bark). It utilizes an isotonic delivery system—a powder that, when mixed with a specific amount of water, creates a solution with the same osmotic pressure as bodily fluids like tears and blood. This formulation is designed to facilitate rapid absorption and high bioavailability of the active flavonoids. The supplement is primarily used to support cardiovascular health by neutralizing reactive oxygen species, reducing inflammation, and improving endothelial function and blood flow.

Brand names
Isotonix OPC-3
Other names
OPC-3OPC3OPC 3
02

Targets

NOS1 (nNOS)

Beyond the preview

Go deeper on Isotonix OPC-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Isotonix OPC-3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call